海南海药：创新药派恩加滨片Ⅱa期临床试验研究结果发布

Core Viewpoint - Hainan Haiyao's subsidiary has successfully completed Phase IIa clinical trials for the innovative drug Paenagabin, which shows promise as a new treatment for refractory epilepsy [1] Group 1: Clinical Trial Results - The Phase IIa clinical trial for Paenagabin has met both primary and secondary clinical endpoints [1] - Paenagabin is classified as a Class 1 chemical drug and is a novel anti-epileptic medication, specifically a next-generation KCNQ potassium channel activator [1] - Currently, there are no marketed products globally for Paenagabin, indicating a unique market opportunity [1] Group 2: Future Development - The completion of Phase IIa is only a preliminary step; further Phase IIb and III clinical trials are required before seeking approval from the National Medical Products Administration for market entry [1] Group 3: Shareholding Changes - Yunnan International Trust plans to reduce its holdings in Hainan Haiyao by up to 12.9737 million shares, representing 1% of the company's total share capital [1]